Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

Nov 09, 2020

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Nov 09, 2020

Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

Nov 06, 2020

Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

Nov 04, 2020

Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting

Nov 04, 2020

Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

Nov 04, 2020

Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab

Nov 02, 2020

Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer

Oct 26, 2020

Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners

Oct 19, 2020

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Oct 12, 2020
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...35
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2021 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Privacy Policy Disclaimer Sitemap